Chapters

Transcript

Video

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

Endocrinology and Metabolism

Endocrinology and Metabolism
University of Manitoba
Principal Investigator
Diabetes Research Group
John Buhler Research Centre
Winnipeg, Manitoba, Canada